Zacks Investment Research downgraded Chiasma Inc (NASDAQ:CHMA) to Sell in a report released today.
- Updated: October 16, 2016
Yesterday Chiasma Inc (NASDAQ:CHMA) traded -1.53% lower at $3.00. The company’s 50-day moving average is $2.76 and its 200-day moving average is $3.64. The last stock close price is down -29.17% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 126,285 shares of the stock were exchanged, down from an average trading volume of 143,617
Zacks Investment Research has downgraded Chiasma Inc (NASDAQ:CHMA) to Sell in a report released on Tuesday October 11, 2016.
Previously on 4/25/2016, Barclays Capital reported about Chiasma Inc (NASDAQ:CHMA) lowered the target price from $40.00 to $5.50. At the time, this indicated a possible upside of 0.44%.
See Chart Below
Chiasma Inc has a 52 week low of $2.40 and a 52 week high of $24.78 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 4 brokerages have issued a ratings update on the company. The average stock price target is $13.13 with 2 brokerages rating the stock a strong buy, two analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and lastly zero analysts rating the company a sell.
General Company Details For Chiasma Inc (NASDAQ:CHMA)
Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company's TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.